Hims & Hers Health, Inc. Class A Common Stock (HIMS)

Hims & Hers Health shares fell 4.1% Wednesday morning. Despite the pullback, the stock remains up an impressive 116% over the past month.

HIMS & HERS HEALTH (NYSE:HIMS) meets Minervini’s Trend Template with strong technicals and explosive earnings growth, making it a high-growth momentum candidate.

CEO Andrew Dudum said it was “more than double what we set out for,” thanks to strong investor demand.

Shares of Hims & Hers have gained 29% over the past week. The move higher has been driven by an impressive Q1 earnings report released last week.

Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative.

Stocks are soaring today on the hope that the trade tensions between the U.S. and China are behind us.

A fundamental analysis of (NYSE:HIMS): HIMS & HERS HEALTH INC (NYSE:HIMS) showing high EPS and FCF growth while beating expectations

The proposal, citing a "Most Favored Nation Policy," fueled debate prompted some watchers to question the legality and feasibility of the move, while others speculated on its potential market impact.

Short interest in Hims & Hers rose to a record high of 37%, continuing a four-week climb, even as the stock surged 42% last week. The company’s quarterly revenue more than doubled, surpassing analyst expectations.

Top-performing large-cap stocks last week: TTD, HIMS, PODD, FTAI, ULS, UI, ROK, TOST, DIS, MCHP, and ARMK. Analysts raised price forecasts.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Hims & Hers is getting $1 billion of rocket fuel.

Hims & Hers Health shares have surged 17.4% this week. The company reported strong first-quarter earnings late Monday.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Hedge funds shorting Hims & Hers Health Inc (NYSE:HIMS) may regret it - earnings with a positive surprise could lead to a short squeeze as stock continues to rise, up 96% in past month.

The company makes immunoglobulin products using donated plasma.

Hims & Hers Health Inc (NYSE:HIMS) shares are falling Thursday morning after the company announced a proposed convertible senior notes offering.

This isn't just any growth stock.

Hims & Hers Health shares have surged 32.4% since Tuesday's session open. The stock is gaining following a standout first-quarter earnings report released late Monday.